Abstract
This year-in-review article provides insights into clinical updates relating to granulocyte-colony stimulating factor (G-CSF) biosimilars research presented at five key congresses in 2022. These include the American Society of Clinical Oncology (ASCO) 55th Annual Meeting (3rd-7th June 2022, Chicago, Illinois, USA), European Society for Medical Oncology (ESMO) Congress (9th-13th September 2022, Paris, France), ESMO Asia Congress (2nd-4th December 2022, Singapore), San Antonio Breast Cancer Symposium (SABCS; 6th-10th December 2022, Texas, USA), and American Society of Hematology (ASH) 64th Annual Meeting and Exposition (10th-13th December 2022, New Orleans, Louisiana, USA). Alongside reviewing the current research presented at these key congresses, with a focus on the use of G-CSF agents and biosimilars in patients undergoing treatment for breast, colorectal, and gynaecological cancers, this article provides an overview of current guidelines on the use of G-CSF in supportive cancer care to manage chemotherapy-induced febrile neutropenia and explores trends in G-CSF biosimilars research.
| Original language | English |
|---|---|
| Pages (from-to) | 16-24 |
| Journal | EMJ |
| Volume | 8 |
| Issue number | 1 |
| Early online date | 16 Mar 2023 |
| DOIs | |
| Publication status | Published - 31 Mar 2023 |
Keywords
- Allied health professions and studies
- G-CSF biosimilar
- breast cancer
- chemotherapy
- colorectal cancer
- febrile neutropenia
- filgrastim
- granulocyte-colony stimulating factor (G-CSF)
- gynaecological cancer
- pegfilgrastim
- primary prophylaxis